Evidence map›Paper›PMID 38222824›Full record

ArticleTranslational neuroscience2023

The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation

Sylwia Wasiak, Li Fu, Emily Daze, Dean Gilham, Brooke D Rakai, Stephanie C Stotz, Laura M Tsujikawa, Chris D Sarsons, Deborah Studer, Kristina D Rinker and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Sylwia WasiakResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Li FuResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Emily DazeResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Dean GilhamResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Brooke D RakaiResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Stephanie C StotzResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Laura M TsujikawaResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Chris D SarsonsResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Deborah StuderDepartment of Biomedical Engineering, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada.
Kristina D RinkerDepartment of Biomedical Engineering, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada.
Ravi JahagirdarResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Norman C W WongResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Michael SweeneyResverlogix Corp., 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Jan O JohanssonResverlogix Corp., 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA.
Ewelina KulikowskiResverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Resverlogix (Canada) · CALibin Cardiovascular Institute of Alberta · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain vascular inflammation is characterized by endothelial activation and immune cell recruitment to the blood vessel wall, potentially causing a breach in the blood - brain barrier, brain parenchyma inflammation, and a decline of cognitive function. The clinical-stage small molecule, apabetalone, reduces circulating vascular endothelial inflammation markers and improves cognitive scores in elderly patients by targeting epigenetic regulators of gene transcription, bromodomain and extraterminal proteins. However, the effect of apabetalone on cytokine-activated brain vascular endothelial cells (BMVECs) is unknown. Here, we show that apabetalone treatment of BMVECs reduces hallmarks of

Indexed as

blood–brain barrierbromodomainepigeneticsinflammationmicrovascular disease

Identifiers

PMID38222824
PMCPMC10787226
OpenAlexW4390725258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.